March 14, 2013

On March 14, 2013, the Committee will meet in open session to discuss FDA’s draft risk assessment model for potential exposure to the variant Creutzfeldt-Jakob disease (vCJD) agent in Red Blood Cells for transfusion in the United States.

• Announcement
• Draft Agenda (PDF - 37KB)
• Draft Quantitative Risk Assessment of vCJD Risk Potentially Associated with the Transfusion of Red Blood Cells in the U.S. (PDF - 834KB)
• Draft Roster (PDF - 69KB)
• FDA Issue Summary (PDF - 300KB)
• Presentations
• Transcript (PDF - 449KB)
• Waivers for Conflicts of Interest
• Webcast